Table of Contents

State/Territory Name: Mississippi

State Plan Amendment (SPA) #: 23-0013

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form
- 3) Approved SPA Page

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



Center for Medicaid and CHIP Services

Medicaid Benefits and Health Programs Group

September 15, 2023

Drew L. Snyder Executive Director Mississippi Division of Medicaid 550 High Street, Suite 1000 Jackson, MS 39201-1399

re: Mississippi State Plan Amendment (SPA) 23-0013

Dear Drew Snyder:

The CMS Division of Pharmacy team has reviewed Mississippi's State Plan Amendment (SPA) 23-0013, received in the CMS Division of Program Operations on July 11, 2023. This amendment proposes to allow the state to add coverage for selected drugs that treat obesity.

Based on the information provided and consistent with the regulations at 42 CFR 447.20, we are pleased to inform you MS-23-0013 is approved with an effective date of July 1, 2023. We are attaching a copy of the signed CMS-179 form, as well as the page approved for incorporation into Mississippi's state plan.

If you have any questions regarding this state plan amendment, please contact Desiree Elekwa Izuakor at 667-290-9590 or desiree.elekwaizuakor@cms.hhs.gov.

Sincerely,

Mickey Morgan Deputy Director, Division of Pharmacy

cc: Robin Bradshaw, Mississippi Division of Medicaid George S. Polles, Mississippi Division of Medicaid Sarah Tadlock, Mississippi Division of Medicaid Etta Hawkins, Mississippi State Lead, CMS

TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES 5. FEDERAL STATUTE/REGULATION CITATION 42 C.F.R. § 447 Section 1927(d)(2) of the Social Security Act 7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT Attachment 3.1-A, Exhibit 12A, Page 1	1. TRANSMITTAL NUMBER 2 3 — 0 0 1 3 MS 3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL SECURITY ACT XIX XXI 4. PROPOSED EFFECTIVE DATE July 1, 2023 6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars) a FFY 23 \$ 3,879,448 b. FFY 24 \$ 15,400,205 8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable) Attachment 3.1-A, Exhibit 12A, Page 1 SPA 19-0004
 SUBJECT OF AMENDMENT State Plan Amendment (SPA) 23-0013 Drugs to Treat Obesity is being submitted to add coverage for selected drugs that treat obesity, effective July 1, 2023. 	
10. GOVERNOR'S REVIEW (Check One) GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED:
12. TYPED NAME Drew L. Snyder 13. TITLE Executive Director 14. DATE SUBMITTED	15. RETURN TO Drew L. Snyder Miss. Division of Medicaid Attn: Robin Bradshaw 550 High Street, Suite 1000 Jackson, MS 39201-1399
7/11/2023 FOR CMS USE ONLY	
16. DATE RECEIVED 07/11/2023 (17. DATE APPROVED 09/15/2023
PLAN APPROVED - ONE COPY ATTACHED 18. EFFECTIVE DATE OF APPROVED MATERIAL 19. SIGNATURE OF APPROVING OFFICIAL	
07/01/2023	19. SIGNATURE OF APPROVING OFFICIAL
20. TYPED NAME OF APPROVING OFFICIAL	21. TITLE OF APPROVING OFFICIAL
Mickey Morgan	Deputy Director, Division of Pharmacy
22. REMARKS	

MEDICAL ASSISTANCE PROGRAM

State of Mississippi

DESCRIPTIONS OF LIMITATIONS AS TO AMOUNT, DURATION AND SCOPE OF MEDICAL CARE AND SERVICES PROVIDED

12a. **Prescribed Drugs**:

- (1) Covered outpatient drugs are those produced by any manufacturer which has entered into and complies with an agreement under Section 1927 (a) of the Act which are prescribed for a medically acceptable indication. Compounded prescriptions (mixtures of two (2) or more ingredients) except for hyperalimentation are not covered.
- (2) All Medicaid non-Early and Period Screening, Diagnostic and Treatment (EPSDT)-eligible beneficiaries are limited to six (6) prescriptions, which includes legend and prescribed OTC drugs, per month with no more than two (2) brand name (single source or innovator multiple source) drugs per month.
 - 1. Preferred brand drugs listed on the Universal Preferred Drug List (PDL) do not count toward the two (2) brand limit, and
 - 2. Over-the-counter (OTC) drugs prescribed by a physician listed on the Division of Medicaid's OTC PDL do not count toward the two (2) brand limit.
- (3) Prescription limits are not applicable for Medicaid beneficiaries receiving institutional long-term care services.
- (4) As provided in Section 1935 (d) (1) of the Act, effective January 1, 2006, the Medicaid agency will not cover any Part D drug for full-benefit dual eligible under Part A or Part B.
- (5) As provided by Sections 1927 (d)(2) and 1935 (d)(2) of the Act, the Medicaid agency provides coverage for the following excluded or otherwise restricted drugs or classes of drugs, or their medical uses, to all Medicaid beneficiaries including full benefit dual eligible beneficiaries under the Medicare prescription Drug Benefit-Part D.

\boxtimes	Select obesity drugs will be covered as listed on the state's website.
	Agents when used to promote fertility;
	Covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee;
	Those drugs designated less than effective by the FDA as a result of the Drug Efficacy Study Implementation (DESI) program;

TN No. <u>23-0013</u> Supersedes TN No. 19-0004 Date Received: <u>07/11/2023</u> Date Approved: <u>09/15/2023</u> Date Effective: <u>07/01/2023</u>